![Roger D. Miller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Roger D. Miller
Voorzitter bij BHI Senior Living, Inc.
Profiel
Roger D.
Miller is currently the Chairman at BHI Senior Living, Inc. He is also the Chief Operating Officer at Apexian Pharmaceuticals, Inc. since 2014 and the Vice President-Operations at Adipo Therapeutics LLC.
In the past, he worked as the Vice President-Operations & Manufacturing at Targanta Therapeutics Corp.
and Targanta Therapeutics, Inc. Mr. Miller completed his undergraduate and graduate degrees from Indiana University-Purdue University and holds an MBA from Krannert School of Management.
Actieve functies van Roger D. Miller
Bedrijven | Functie | Begin |
---|---|---|
BHI Senior Living, Inc.
![]() BHI Senior Living, Inc. Hospital/Nursing ManagementHealth Services BHI Senior Living, Inc. provides continuing care retirement communities to offer private maintenance-free residences for active seniors. Its communities offer services in the areas of housekeeping, transportation, and security services; various amenities, such as fitness centers, performing arts centers, and various dining venues; engaging activities ranging from musical entertainment and trips to interesting regional sites; and on-site care that includes assisted living, memory care, skilled nursing, and rehabilitation services. The company was founded by Edward Crawford and Sarah Crawford on June 27, 1904 and is headquartered in Indianapolis, IN. | Voorzitter | - |
Apexian Pharmaceuticals, Inc.
![]() Apexian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. The company was founded by Mark R. Kelley in 2005 and is headquartered in Indianapolis, IN. | Operationeel Directeur | 01-11-2014 |
Adipo Therapeutics LLC
![]() Adipo Therapeutics LLC Pharmaceuticals: MajorHealth Technology Adipo Therapeutics LLC developing a technology platform of localized, polymer-based nanoparticulate delivery of Notch inhibitors to induce adipocyte browning in specific white fat depots. Its treatment offers the potential of a value proposition for the treatment of type 2 diabetes, providing sustainable weight loss, improved glucose homeostasis and systemic metabolism, with minimized off-target side effects. The company was founded by Meng Deng and is headquartered in West Lafayette, IN. | Operationeel Directeur | - |
Eerdere bekende functies van Roger D. Miller
Bedrijven | Functie | Einde |
---|---|---|
Targanta Therapeutics Corp.
![]() Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | Corporate Officer/Principal | - |
Targanta Therapeutics, Inc.
![]() Targanta Therapeutics, Inc. BiotechnologyHealth Technology Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada | Operationeel Directeur | - |
Opleiding van Roger D. Miller
Indiana University-Purdue University | Graduate Degree |
Krannert School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Targanta Therapeutics Corp.
![]() Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | Health Technology |
Targanta Therapeutics, Inc.
![]() Targanta Therapeutics, Inc. BiotechnologyHealth Technology Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada | Health Technology |
BHI Senior Living, Inc.
![]() BHI Senior Living, Inc. Hospital/Nursing ManagementHealth Services BHI Senior Living, Inc. provides continuing care retirement communities to offer private maintenance-free residences for active seniors. Its communities offer services in the areas of housekeeping, transportation, and security services; various amenities, such as fitness centers, performing arts centers, and various dining venues; engaging activities ranging from musical entertainment and trips to interesting regional sites; and on-site care that includes assisted living, memory care, skilled nursing, and rehabilitation services. The company was founded by Edward Crawford and Sarah Crawford on June 27, 1904 and is headquartered in Indianapolis, IN. | Health Services |
Apexian Pharmaceuticals, Inc.
![]() Apexian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. The company was founded by Mark R. Kelley in 2005 and is headquartered in Indianapolis, IN. | Health Technology |
Adipo Therapeutics LLC
![]() Adipo Therapeutics LLC Pharmaceuticals: MajorHealth Technology Adipo Therapeutics LLC developing a technology platform of localized, polymer-based nanoparticulate delivery of Notch inhibitors to induce adipocyte browning in specific white fat depots. Its treatment offers the potential of a value proposition for the treatment of type 2 diabetes, providing sustainable weight loss, improved glucose homeostasis and systemic metabolism, with minimized off-target side effects. The company was founded by Meng Deng and is headquartered in West Lafayette, IN. | Health Technology |